Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v3-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2026-01-08 | Was: 2026-01-22 |
| Drug Identification Number | 02172917 | 02172917 |
| Brand name | CALMYLIN PSE WITH CODEINE | CALMYLIN PSE WITH CODEINE |
| Common or Proper name | CALMYLIN PSE WITH CODEINE SYRUP | CALMYLIN PSE WITH CODEINE SYRUP |
| Company Name | TEVA CANADA LIMITED | TEVA CANADA LIMITED |
| Ingredients | PSEUDOEPHEDRINE HYDROCHLORIDE GUAIFENESIN CODEINE PHOSPHATE | PSEUDOEPHEDRINE HYDROCHLORIDE GUAIFENESIN CODEINE PHOSPHATE |
| Strength(s) | 30MG 100MG 3.3MG | 30MG 100MG 3.3MG |
| Dosage form(s) | SYRUP | SYRUP |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size (Changed) | Updated to: 100ml | Was: 100 & 250ml |
| Additional packaging sizes | ||
| ATC code | R05FA | R05FA |
| ATC description | COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS | COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2026-01-07 | 2026-01-07 |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | On Suspended Supply | On Suspended Supply |
| Health Canada comments |